喹硫平合并舍曲林治疗伴抑郁症状精神分裂症患者对照研究

摘要

目的 探讨喹硫平合并舍曲林治疗伴抑郁症状精神分裂症患者的疗效及安全性.方法 将123例伴有抑郁症状的精神分裂症患者随机分成研究组63例和对照组60例,研究组应用喹硫平合并舍曲林系统治疗,对照组应用喹硫平系统治疗,共8周.在基线及治疗后第2、4、8周末分别采用阳性和阴性综合征量表(PANSS)、临床总体印象量表(CGI)及副反应量表(TESS)以评定疗效和安全性.结果 在治疗后第2、4、8周末,研究组PANSS的Kay因子分均显著低于对照组,且差异均有显著性意义(P＜0.05).在治疗后第4、8周末,研究组PANSS的阴性因子分和总分均显著低于对照组,且均有统计学意义(P＜0.05).在治疗后笫4、8周末,研究组的CGI评分均显著低于对照组,差异均具有显著性(P＜0.05).两组均无严重不良反应.结论 喹硫平合并舍曲林可有效、快速改善伴抑郁症状精神分裂症患者的抑郁症状及阴性症状,安全性较高.%Objective To explore the efficacy and side effects of quetiapine combined with sertraline for schizophrenic patients with depressive symptoms. Methods A total of 123 schizophrenic patients with depressive symptoms were randomly divided into study group (63 cases) treated with quetiapine combined with sertraline and control group (60 cases) treated with quetiapine monotherapy for 8 weeks. The efficacy and side effects were evaluated with Positive and Negative Symptoms Scales (PANSS) , Clinical Global Impression ( CGI) and Treatment Emergent Symptom Scale (TESS) at baseline and at the 2nd, 4th, 8th weekend of the treatment. Results Kay factor score of PANSS in study group were significantly lower than that in control group (P <0. 05) at the 2nd, 4th and 8th weekend of the treatment. At the 4th and 8th weekend, total score of PANSS and factor score of negative symptoms in study group were significantly lower than those in control group (P < 0.05 ). Score of CGI in study group was significantly lower than that in control group (P < 0. 05) at the 4th and 8th weekend. There was no severe side effects in two groups. Conclusion Quetiapine combined with sertraline can improve depressive symptoms and negative symptoms effectively and rapidly in schizophrenic patients with depressive symptoms.